期刊文献+

Why,who and how should perform liver biopsy in chronic liver diseases 被引量:12

Why,who and how should perform liver biopsy in chronic liver diseases
下载PDF
导出
摘要 Chronic viral hepatitis is a common disease in the general population.During chronic hepatitis,the prognosis and clinical management are highly dependent on the extent of liver fibrosis.The fibrosis evaluation can be performed by FibroTest(using serological markers),by Elastography or FibroScan(a noninvasive percutaneous technique using the elastic properties of the hepatic tissue) and by liver biopsy(LB),considered to be the "gold standard".Currently,there are three techniques for performing LB:percutaneous,transjugular and laparoscopic.The percutaneous LB can be performed blind,ultrasound(US) guided or US assisted.There are two main categories of specialists who perform LB:gastroenterologists(hepatologists) and radiologists,and the specialty of the individual who performs the LB determines if the LB is performed under ultrasound guidance or not.There are two types of biopsy needles used for LB:cutting needles(Tru-Cut,Vim-Silverman) and suction needles(Menghini,Klatzkin,Jamshidi).The rate of major complications after percutaneous LB ranges from 0.09% to 2.3%,but the echo-guided percutaneous liver biopsy is a safe method for the diagnosis of chronic diffuse hepatitis(cost-effective as compared to blind biopsy) and the rate of complications seems to be related to the experience of the physician and the type of the needle used(Menghini type needle seems to be safer).Maybe,in a few years we will use non-invasive markers of fibrosis,but at this time,most authorities in the field consider that the LB is useful and necessary for the evaluation of chronic hepatopathies,despite the fact that it is not a perfect test. Chronic viral hepatitis is a common disease in the general population.During chronic hepatitis,the prognosis and clinical management are highly dependent on the extent of liver fibrosis.The fibrosis evaluation can be performed by FibroTest(using serological markers),by Elastography or FibroScan(a noninvasive percutaneous technique using the elastic properties of the hepatic tissue) and by liver biopsy(LB),considered to be the "gold standard".Currently,there are three techniques for performing LB:percutaneous,transjugular and laparoscopic.The percutaneous LB can be performed blind,ultrasound(US) guided or US assisted.There are two main categories of specialists who perform LB:gastroenterologists(hepatologists) and radiologists,and the specialty of the individual who performs the LB determines if the LB is performed under ultrasound guidance or not.There are two types of biopsy needles used for LB:cutting needles(Tru-Cut,Vim-Silverman) and suction needles(Menghini,Klatzkin,Jamshidi).The rate of major complications after percutaneous LB ranges from 0.09% to 2.3%,but the echoguided percutaneous liver biopsy is a safe method for the diagnosis of chronic diffuse hepatitis(cost-effective as compared to blind biopsy) and the rate of complications seems to be related to the experience of the physician and the type of the needle used(Menghini type needle seems to be safer).Maybe,in a few years we will use non-invasive markers of fibrosis,but at this time,most authorities in the field consider that the LB is useful and necessary for the evaluation of chronic hepatopathies,despite the fact that it is not a perfect test.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2008年第21期3396-3402,共7页 世界胃肠病学杂志(英文版)
关键词 Chronic hepatitis Liver biopsy FIBROSIS Ultrasound guidance 慢性肝炎 肝活组织检查 纤维化 超声检查
  • 相关文献

参考文献60

  • 1[1]Lai CL,Ratziu V,Yuen MF,Poynard T.Viral hepatitis B.Lancet 2003;362:2089-2094
  • 2[2]Global surveillance and control of hepatitis C.Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board,Antwerp,Belgium.J Viral Hepat 1999;6:35-47
  • 3[3]Alter MJ,Kruszon-Moran D,Nainan OV,McQuillan GM,Gao F,Moyer LA,Kaslow RA,Margolis HS.The prevalence of hepatitis C virus infection in the United States,1988 through 1994.N Engl J Med 1999;341:556-562
  • 4[4]Ioannou GN,Weiss NS,Kowdley KV,Dominitz JA.Is obesity a risk factor for cirrhosis-related death or hospitalization? A population-based cohort study.Gastroenterology 2003;125:1053-1059
  • 5[5]EI-Serag HB,Tran T,Everhart JE.Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma.Gastroenterology 2004;126:460-468
  • 6[6]Fontolliet CH.Role de la biopsie dans le diagnostic et le traitement de l'hepatite chronique C.Med Hyg 2001;59:2179-2182.Available from:URL:http://www.revmed.ch/article.php3?sid =21734
  • 7[7]Everhart JE,Stolar M,Hoofnagle JH.Management of hepatitis C:a national survey of gastroenterologists and hepatologists.Hepatology 1997;26:78S-82S
  • 8[8]Perrillo RP.The role of liver biopsy in hepatitis C.Hepatology 1997;26:57S-61S
  • 9[9]Saadeh S,Cammell G,Carey WD,Younossi Z,Barnes D,Easley K.The role of liver biopsy in chronic hepatitis C.Hepatology 2001;33:196-200
  • 10[10]Bravo AA,Sheth SG,Chopra S.Liver biopsy.N Engl J Med 2001;344:495-500

同被引文献40

引证文献12

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部